Cargando...
Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities
Oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) occur in 15%–30% of non-small cell lung cancer (NSCLC). However, despite decades of intensive research, there is still no direct KRAS inhibitor with clinically proven efficacy. Considering its association with poor treatment re...
Gardado en:
| Publicado en: | Acta Biochim Biophys Sin (Shanghai) |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Oxford University Press
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4689161/ https://ncbi.nlm.nih.gov/pubmed/26578706 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/abbs/gmv118 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|